It has been shown that both 5-FU and carboplatin specifically induce the expression of Hsp27 and Hsp40 in the studied cells, indicating that the upregulation of these factors is a survival mechanism in response to treatment, which leads to the conclusion that the use of inhibitors targeting Hsp27/Hsp40 or the implementation of knockdown strategies for Hsp27/Hsp40, in conjunction with chemotherapeutic agents, could serve as a reasoned therapeutic approach for HCC [94]. Here, DNAJB1 is linked to hepatocellular carcinoma.